Search our Database of Scientific Publications and Authors

I’m looking for a

    949 results match your criteria Lupus Erythematosus Drug-Induced

    1 OF 19

    Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients.
    Eur J Rheumatol 2017 Jun 11;4(2):87-92. Epub 2017 Apr 11.
    Division of Rheumatology Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.
    Objective: Systemic lupus erythematosus (SLE) may affect a number of systems, with the hematological system being one of the most common. Our aim is to determine the existence of cytopenia at diagnosis or during follow-up of our SLE patients as well as the associated factors.

    Material And Methods: A cohort of SLE patients that had been followed-up in the Department of Rheumotology from 1998 to 2015 was retrospectively assessed. Read More

    The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests.
    Lupus 2017 Jan 1:961203317709344. Epub 2017 Jan 1.
    1 Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Florence, Italy.
    Background Anti-double stranded DNA antibodies are a very heterogeneous group of antibodies, quite specific for systemic lupus erythematosus. Newer technologies, such as addressable laser bead immunoassays (ALBIA), show great potential as a diagnostic application. The production of anti-double stranded DNA antibodies is often encountered in inflammatory arthritis; however, literature reports that the actual onset of drug induced lupus in patients treated with biological drugs is a rare event. Read More

    Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.
    BMC Nephrol 2017 May 12;18(1):157. Epub 2017 May 12.
    Nephropathology Service, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Uberaba, MG, CEP: 38015-050, Brazil.
    Background: Fabry Disease (FD) is a genetic disorder caused by alpha-galactosidase A deficiency. Certain drugs, such as hydroxychloroquine, can produce renal deposits that mimic morphological findings seen in FD, characterizing a type of drug-induced renal phospholipidosis.

    Case Presentation: Case 1: A 28-year-old female patient with systemic lupus erythematosus who had been using hydroxychloroquine for 14 months presented subnephrotic proteinuria. Read More

    Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series.
    J Peripher Nerv Syst 2017 Sep;22(3):213-218
    Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.
    We describe six patients with cutaneous lupus erythematosus (cLE) during immunoglobulin G (IgG) treatment. Five patients were diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and one patient with possible CIDP. Five patients received intravenous immunoglobulin (IVIg) and one patient received subcutaneous immunoglobulin (SCIg). Read More

    Hydroxychloroquine-induced erythroderma.
    Indian J Pharmacol 2017 Jan-Feb;49(1):132-134
    Department of Pathology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India.
    Erythroderma is characterized by diffuse erythema and scaling of the skin involving more than 90% of the total body skin surface area. Drug-induced erythroderma has rarely been reported with hydroxychloroquine. We report a case of a 50-year-old female patient, with systemic lupus erythematosus, who developed itchy lesions all over the body 1 month after starting treatment with hydroxychloroquine. Read More

    Persistent Afebrile Abdominal Pain: An Unusual Case of Segmental Colitis in an Immunocompromised Host.
    Cureus 2017 Feb 16;9(2):e1033. Epub 2017 Feb 16.
    4th Internal Medicine Department, "Evangelismos" General Hospital, Athens, Greece.
    In this report we describe a case of a 66-year-old woman who presented with right upper quadrant abdominal pain and bloody diarrhea. A workup revealed immunodeficiency, an immunologic profile with low complement levels resembling systemic lupus erythematosus, and a circumferential colonic wall lesion located in the ascending colon. After endoscopy and biopsy, the mass lesion was attributed to "double hit" diffuse large B-cell lymphoma, categorized as high grade large B-cell non-Hodgkin lymphoma according to the most recent revised 2016 World Health Organisation classification and considered to be a rare and highly aggressive tumor. Read More

    Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands.
    Lupus Sci Med 2017 13;4(1):e000207. Epub 2017 Mar 13.
    The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
    Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Read More

    An update in drug-induced subacute cutaneous lupus erythematosus.
    Dermatol Online J 2017 Mar 15;23(3). Epub 2017 Mar 15.
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.
    Background: It has been over three decades sincethe first report of drug-induced subacute cutaneouslupus erythematosus (DI-SCLE) was described. Withan increasing variety of implicated drugs and thepotential for publication bias, we must consider: 1) hasthere been a change in drugs most often reported inDI-SCLE over time, and, 2) if so, of which drugs shouldclinicians be most suspicious in the setting of possibleDI-SCLE?

    Objective: To determine which drug(s) present thehighest risk for inducing DI-SCLE.

    Methods: The PubMed database was queried forreports of DI-SCLE from August, 2009 until May,2016. Read More

    Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.
    J Adv Res 2016 Sep 23;7(5):719-726. Epub 2016 Apr 23.
    Department of Medical Oncology, Ioannina University Hospital, S. Niarchos Avenue, 45500 Ioannina, Greece.
    Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous manifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with specific serum autoantibodies (i.e. antinuclear antibodies (ANA), Ro/SSa, La/SSb). Read More

    The "red face": Not always rosacea.
    Clin Dermatol 2017 Mar - Apr;35(2):201-206. Epub 2016 Oct 27.
    Department of Dermatology, Andreas Syggros Hospital, University of Athens, 5, Dragoumi str, Athens, 16121, Greece. Electronic address:
    Facial erythema (the "red face") is a straightforward clinical finding, and it is evident even to the untrained eye; however, a red face does not represent a single cutaneous entity. It may be due to a plethora of distinct underlying conditions of varying severity, including rosacea, demodicosis, dermatomyositis, lupus erythematosus, allergic contact dermatitis, drug-induced erythema, and emotional blushing. In clinical practice, dermatologists do not encounter only one type of facial erythema but rather a number of different shades of red. Read More

    Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.
    Case Rep Rheumatol 2017 17;2017:5245904. Epub 2017 Jan 17.
    Department of Internal Medicine, Seton Hall University School of Health and Medical Sciences, Saint Francis Medical Center, Trenton, NJ, USA.
    Drug induced lupus erythematosus (DIL or DILE) is an autoimmune disorder caused by chronic use of certain drugs. We report a unique case of hydralazine induced lupus syndrome (HILS) with a negative antinuclear antibody in a female patient who was on hydralazine for a period of 1.5-2 years and developed recurrent pericardial effusion as a result of it. Read More

    A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus.
    J Clin Pharm Ther 2017 Jun 12;42(3):363-366. Epub 2017 Feb 12.
    Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
    What Is Known And Objective: Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus.

    Case Description: We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. Read More

    Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.
    Mayo Clin Proc 2017 Mar 6;92(3):406-414. Epub 2017 Feb 6.
    Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address:
    Objective: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE).

    Patients And Methods: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed.

    Results: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases). Read More

    Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Transpl Infect Dis 2017 Apr 22;19(2). Epub 2017 Feb 22.
    Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA.
    We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)-negative donor to three HCV-negative recipients-two renal transplants and one liver. Both renal recipients underwent standard deceased-donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. Read More

    [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    • Authors:
    • ,
    Zhonghua Nei Ke Za Zhi 2017 Jan;56(1):81-85
    Non-steroidal anti-inflammatory drugs (NSAIDs) are a broad class of non glucocorticoid drugs which are extensively used in anti-inflammatory, analgesic, and antipyretic therapies. However, NSAIDs may cause many side effects, most commonly in gastrointestinal(GI) tract. Cardiovascular system, kidney, liver, central nervous system and hematopoietic system are also involved. Read More

    Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/lpr mice by Regulating Th17 Cell Function.
    Sci Rep 2016 Dec 12;6:38619. Epub 2016 Dec 12.
    Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
    Lupus nephritis (LN) is the major clinical manifestation of systemic lupus erythematosus. LN is promoted by T helper 17 (Th17) cells, which are the major pro-inflammatory T cell subset contributing to autoimmunity regulation. Nuclear factor erythroid 2-related factor 2 (NRF2) is critical for suppressing reactive oxygen species (ROS) and relieving oxidant stress by regulating antioxidant gene expression. Read More

    Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.
    J Clin Diagn Res 2016 Oct 1;10(10):OD06-OD07. Epub 2016 Oct 1.
    Intern, Department of Medicine, Pt. BD Sharma PGIMS , Rohtak, Haryana, India .
    Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Read More

    Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia.
    J Clin Diagn Res 2016 Oct 1;10(10):OD03-OD05. Epub 2016 Oct 1.
    Professor, Department of Pulmonary Medicine, D.Y. Patil Medical College and Hospital , Mumbai, Maharashtra, India .
    Drug Induced Lupus Erythematous (DILE) is a rare adverse reaction to a large variety of drugs including Isoniazid (INH), with features resembling idiopathic Systemic Lupus Erythematosus (SLE). Diagnosis require identification of a temporal relationship between drug administered and symptom. It is an idiosyncratic reaction, with no pre-existing lupus. Read More

    Treatment of antiviral-resistant recurrent erythema multiforme with dapsone.
    Dermatol Ther 2017 Mar 18;30(2). Epub 2016 Nov 18.
    Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL.
    Recurrent erythema multiforme (REM) is a chronic disease characterized by frequent episodes of target cutaneous lesions in an acral distribution. Conventional treatment includes systemic corticosteroids and antiviral therapy. The aim of this study was to evaluate dapsone as a potential steroid sparing-agent for the treatment of REM after a failed trial of at least one antiviral therapy (acyclovir, famciclovir, or valacyclovir). Read More

    Drug-induced cutaneous lupus erythematosus: 88 new cases.
    Eur J Dermatol 2017 Feb;27(1):28-33
    Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000, Odense C, Denmark.
    Background: An increasing number of drugs have been linked to drug-induced subacute cutaneous lupus erythematosus (DI-SCLE). The recognition and management of DI-SCLE can be challenging, as the condition may be triggered by different classes of drugs after variable lengths of time.

    Objectives: To determine the proportion of patients with cutaneous lupus erythematosus (CLE) whose drugs are an inducing or aggravating factor. Read More

    TNF-alpha antagonist induced lupus on three different agents.
    Postgrad Med 2017 Mar 28;129(2):304-306. Epub 2016 Oct 28.
    c Department of Gastroenterology , Lenox hill Hospital , New York , NY , USA.
    Tumor necrosis factor alpha (TNF alpha) antagonists are biologic agents used in the management of inflammatory conditions such as rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory bowel disease. These agents have been recently shown to cause a syndrome called anti-TNF induced lupus (ATIL), a rare condition which has similar clinical manifestations to idiopathic systemic lupus erythematosus (SLE). Given that extra-intestinal manifestations of inflammatory bowel disease include arthritis, it can be difficult to separate arthritis due to underlying disease from drug-induced arthritis. Read More

    Wilson's Disease with Systemic Lupus Erythematosus.
    J Assoc Physicians India 2016 Apr;64(4):81-82
    Professor and Head, Department of General Medicine, Coimbatore Medical College Hospital, Coimbatore, Tamil Nadu.
    Case reports of Wilson's disease occurring in combination with SLE are rarely reported in literature. Drug induced lupus have been observed in patients taking D-penicillamine for Wilson's disease. Here we report a case from Coimbatore Medical College hospital, who presented with fever and neuropsychiatric symptoms as the initial manifestation and found to have both SLE and Wilson's disease on subsequent evaluation. Read More

    Anastrozole-induced subacute cutaneous lupus erythematosus.
    Cutis 2016 Aug;98(2):E22-6
    Northwell Department of Dermatology, Hofstra-Northwell School of Medicine, Hempstead, New York, USA.
    Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) has been associated with numerous drugs, but there are limited reports of its association with aromatase inhibitor anastrozole. We report the case of a patient undergoing treatment with anastrozole for breast cancer who presented with clinical, serological, and histological evidence consistent with DI-SCLE. Her condition quickly began to improve after the use of anastrozole was discontinued and hydroxychloroquine therapy was initiated. Read More

    [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].
    Hautarzt 2016 Sep;67(9):724-31
    , Hofmannstr. 11, 35444, Biebertal, Deutschland.
    Based on the technical information that oral terbinafine must be used with caution in patients with pre-existing psoriasis or lupus erythematosus, the literature was summarized. Terbinafine belongs to the drugs able to induce subcutaneous lupus erythematosus (SCLE)-with a relatively high risk. The clinical picture of terbinafine-induced SCLE may be highly variable and can also include erythema exsudativum multiforme-like or bullous lesions. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
    Drugs Real World Outcomes 2016 Jun 29;3(2):145-154. Epub 2016 Mar 29.
    The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210 USA.
    Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify passive pharmacovigilance signals for SCLE associated with PPIs. Read More

    A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade.
    Lupus 2017 Mar 11;26(3):316-319. Epub 2016 Jul 11.
    Pulmonary, Critical Care and Sleep Medicine Division, The George Washington University, Washington, DC, USA.
    We report a case of drug-induced lupus erythematosus (DILE) secondary to trimethoprim/sulfamethoxazole (TMP/SMX) in a patient with underlying inflammatory bowel disease (IBD). The initial presentation was with febrile pleural and pericardial effusions followed by cardiac tamponade. The patient was treated with a short course of corticosteroids with complete resolution of symptoms. Read More

    Toxic Epidermal Necrolysis-Like Cutaneous Lupus in Pediatric Patients: A Case Series and Review.
    Pediatrics 2016 Jun;137(6)
    Division of Pediatric Dermatology, Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin;
    Bullous eruptions in patients with underlying systemic lupus erythematosus (LE) can mimic toxic-epidermal necrolysis (TEN), a rapidly progressive mucocutaneous reaction usually associated with medication use. Differentiating between classic drug-induced TEN and TEN-like cutaneous LE is important but difficult. We report a series of 3 patients with pediatric systemic LE who were admitted with severe worsening of skin disease resembling TEN. Read More

    Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.
    Pharmacoepidemiol Drug Saf 2016 Aug 2;25(8):908-17. Epub 2016 Mar 2.
    Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
    Purpose: Antituberculosis drug-induced liver injury (ATDILI) is one of the most deleterious side effects associated with chemotherapy against tuberculosis (TB). In this study, our objective was to determine the incidence, risk factors, and management of ATDILI and analyze its impact on the treatment outcome in patients receiving standard anti-TB chemotherapy.

    Methods: A prospective cohort study of ATDILI prevalence was conducted in 938 enrolled patients of the 1426 TB cases in Shanghai from March 2011 to September 2012. Read More

    [Clinical analysis of 6 patients with drug-induced lupus].
    Zhonghua Nei Ke Za Zhi 2016 Mar;55(3):211-5
    Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
    Objective: To improve the understanding of drug-induced lupus (DIL) and the differences from systemic lupus erythematosus (SLE).

    Methods: Clinical manifestation and treatment of patients with definite DIL were retrospectively analyzed.

    Results: Six patients with DIL were enrolled in this study, including 4 females and 2 males. Read More

    Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.
    Curr Allergy Asthma Rep 2016 Mar;16(3):17
    Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA.
    PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions are rare but increasingly recognized adverse effects of proton pump inhibitors (PPIs). Immediate hypersensitivity reactions can occur due to IgE-mediated hypersensitivity to PPIs and can be evaluated by immediate hypersensitivity skin testing and oral provocation challenge testing. Read More

    Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia.
    Rom J Intern Med 2015 Jul-Sep;53(3):282-5
    Drug induced lupus erythematosus (DLE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Read More

    Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice.
    Zhongguo Zhong Yao Za Zhi 2015 Jul;40(13):2537-41
    Tripterygium wilfordii has exihibited multiple pharmacological activities, such as anti-inflammatory, immune modulation, anti-tumor and anti-fertility. T. wilfordii have been used for the therapy of inflammation and autoimmune diseases including rheumatoid arthritis, immune complex nephritis and systemic lupus erythematosus clinically. Read More

    [DRUG-INDUCED LUPUS CAUSED BY LONG TERM MINOCYCLINE TREATMENT FOR ACNE VULGARIS].
    Arerugi 2015 Sep;64(9):1269-73
    Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University.
    An 18-year-old Japanese girl had received oral minocycline 200mg daily for treatment of acne vulgaris since 16 years old. She had a fever three months before admission, followed by joint pains in her knees, elbows and several proximal interphalangeal joints one month before admission. She was referred to our hospital because of a high serum level of anti-DNA antibody. Read More

    [Drug-induced acute kidney injury].
    Ther Umsch 2015 Dec;72(11-12):717-27
    1 Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie, Inselspital Bern.
    Due to their physiological function, the kidneys are exposed to high concentrations of numerous drugs and their metabolites, making them vulnerable to drug-related injuries. This article provides an overview of the pathophysiological mechanisms involved in nephrotoxicity, the most common nephrotoxic drugs, and the risk factors for the occurrence of drug-induced acute kidney injuries. NSAIDs, diuretics, ACE inhibitors, and angiotensin II receptor blockers (ARBs} are the most frequent prerenal causes of an acute elevation in creatinine levels. Read More

    Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.
    Am J Clin Dermatol 2016 Apr;17(2):147-62
    Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, 41 Avenue Louis Pasteur, Suite 319, Boston, MA, 02115, USA.
    Rheumatoid arthritis (RA) is a systemic inflammatory disorder that primarily affects the joints, but may exhibit extra-articular, including cutaneous, manifestations such as rheumatoid nodules, rheumatoid vasculitis, granulomatous skin disorders, and neutrophilic dermatoses. A large burden of cutaneous disease may be an indication of RA disease activity and the need for more aggressive treatment. Many of the therapeutic agents used to treat RA can also result in cutaneous adverse effects, which pose their own diagnostic and therapeutic challenges. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.
    Am J Ther 2016 Nov/Dec;23(6):e1965-e1967
    Department of Medicine, New York Medical College, Metropolitan Hospital Center, New York, NY.
    Hepatitis C infection and its treatment have been associated with extrahepatic manifestations, including different skin conditions. Over the past decades, a greater number of drugs have been implicated as triggers for drug-induced subacute cutaneous lupus erythematosus. We report a case of a 42-year-old Hispanic man who developed a forehead violaceous rash during treatment with pegylated interferon alpha-2a as part of his therapy against hepatitis C infection that subsequently resulted to be subacute cutaneous lupus erythematosus. Read More

    New-onset systemic lupus erythematosus in a long-term hemodialysis patient with acute pleuritis and pneumonitis.
    CEN Case Rep 2015 Nov 7;4(2):139-144. Epub 2014 Nov 7.
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
    A 61-year-old woman, with a 25-year history of maintenance hemodialysis due to end-stage renal disease of unknown causes, was admitted because of systemic joint pain and inflammatory response of unknown etiology that persisted for 1 month. Laboratory data on admission revealed leukocytopenia, lymphocytopenia, high serum C-reactive protein, and positivity for antinuclear antibody (ANA) and anti-double strand DNA. After admission, she progressively developed cough and dyspnea. Read More

    Secondary angle closure glaucoma by lupus choroidopathy as an initial presentation of systemic lupus erythematosus: a case report.
    BMC Ophthalmol 2015 Oct 29;15:148. Epub 2015 Oct 29.
    Department of Ophthalmology, Kyung Hee University Hospital at Gangdong, Kyung Hee University, 892, Dongnam-ro, Gangdong-gu, Seoul, 05278, Korea.
    Background: We present a rare case of secondary angle closure glaucoma due to systemic lupus erythematosus choroidopathy as initial presentation of systemic lupus erythematosus, accompanied by central nervous system vasculitis and uncontrolled nephropathy.

    Case Presentation: A 31-year-old woman presented with decreased visual acuity, nausea, vomiting, fever, and bilateral angioedema-like eyelid swelling. She had persistent dry cough while taking medication for 3 months, and had usual posterior neck pain, which was treated with analgesic medication and Asian medicines. Read More

    [Secondary humoral immunodeficiency in patiens with systemic lupus erythematosus].
    Vnitr Lek 2015 Sep;61(9):778-84
    Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease. The aim of our study was to clarify the frequency of decreased serum immunoglobulin levels in SLE patients. There were evaluated 799 results of serum immunoglobulin levels gained from 157 patients fulfilling revised ACR criteria in the retrospective study. Read More

    Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine.
    Australas J Dermatol 2017 Feb 30;58(1):e20-e22. Epub 2015 Sep 30.
    Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain.
    Drug-induced lupus erythematosus (DILE) is a less severe variant of systemic lupus erythematosus (SLE) that generally resolves within weeks or months after the withdrawal of the implicated drug. DILE is unusual during childhood, with the most frequent age of presentation being at 50-70 years of age. Among different drugs, most commonly procainamide and hydralazine have been implicated as a cause of DILE. Read More

    Drug-induced lupus erythematosus associated with donepezil: a case report.
    Age Ageing 2015 Nov 28;44(6):1062-3. Epub 2015 Sep 28.
    Alzheimer Evaluation Unit, ASL Napoli Centro, Naples, Italy.
    The possibility that drug-induced lupus erythematosus (DILE) can be induced by donepezil is presented in this clinical case. Donepezil is an inhibitor of acetylcholinesterase used for the treatment of Alzheimer's disease. It is the first time that donepezil causes DILE. Read More

    Coexistence of Fetal Cardiac Malformation and Maternal Drug-Induced Lupus: Is Lamotrigine Safe?
    Am J Ther 2016 Sep-Oct;23(5):e1263-5
    1Division of Neonatology, Aydin Maternity and Children's Hospital, Aydin, Turkey; and 2Departments of Neonatology and 3Pediatric Cardiology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
    Lamotrigine (LTG) is a widely used second-generation antiepileptic drug for long-term therapy of epileptic patients. Although LTG monotherapy during pregnancy is assumed to be relatively safe, teratogenic effects related to LTG has been reported previously. The presence of fetal malformations and maternal drug-induced lupus erythematosus concurrently in a pregnant women using LTG have not been reported before. Read More

    A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production.
    Biochem Pharmacol 2015 Dec 25;98(4):659-70. Epub 2015 Sep 25.
    Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
    Acebutolol, a β-adrenergic receptor-blocker, occasionally causes drug-induced lupus erythematosus (DILE). Acebutolol is mainly metabolized to diacetolol. Because metabolic activation has been considered to be related to acebutolol-induced toxicity, we sought to identify the enzymes that are responsible for acebutolol metabolism and investigate their involvement in acebutolol-induced toxicity. Read More

    1 OF 19